Table 2.
Study‐Drug Use and BP Achieved After 24 Months of Treatment
| Never, n = 4798 | Resolved, n = 4070 | New Onset, n = 899 | Persistent, n = 7184 | P Value | |
|---|---|---|---|---|---|
| Mean (median) study‐drug dose, mg | |||||
| Verapamil | 297 (240) | 282 (240) | 305 (240) | 311 (360) | <0.0001 |
| Atenolol | 72 (50) | 76 (50) | 80 (75) | 82 (100) | <0.0001 |
| Trandolapril | 4.1 (4) | 3.6 (4) | 4.1 (4) | 4.1 (4) | <0.0001 |
| HCTZ | 29 (25) | 29.7 (25) | 29.5 (25) | 29.9 (25) | 0.0008 |
| Mean SBP at 24 months, mm Hg (SD) | 134.1 (16.0) | 133.0 (15.9) | 133.9 (18.2) | 132.5 (6.3) | <0.0005 |
| Mean DBP at 24 months, mm Hg (SD) | 75.6 (9.8) | 77.9 (9.2) | 75.8 (10.5) | 77.6 (9.2) | <0.0001 |
| BP control at 24 months, %a | 67 | 69 | 65 | 68 | 0.17 |
Abbreviations: BP, blood pressure; DBP, diastolic blood pressure; HCTZ, hydrochlorothiazide; SBP, systolic blood pressure; SD, standard deviation.
a
<140/90 mm Hg.